Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in ... Read More
VectivBio initiates phase 3 trial of apraglutide in patients with short bowel syndrome
VectivBio, a leading Swiss biotechnology firm, has announced the commencement of patient dosing in its phase 3 STARS clinical trial. This trial will evaluate the ... Read More